Wednesday, January 06, 2010

Government Programs Summit

The event will be moderated by Chris Cobourn, Vice President of Regulatory Compliance at CIS and a friend of Drug Channels. CIS’ Pharma Compliance Blog is included in our blog roll.

Drug Channels readers understand the importance of government programs and pricing issues, so I encourage you to check out this event. Below are some details courtesy of IIR. Click here to see the agenda and list of speakers, which includes many folks from agencies such as the Center for Medicare & Medicaid Services (CMS) and Department of Veterans Affairs.OVERVIEW

Government programs are growing increasingly complicated and risky for any pharmaceutical manufacturer, especially with the changes proposed in Healthcare Reform from the Obama Administration. Beginning in Q1 2010, every manufacturer’s pricing methodologies and calculations will significantly be impacted due to the adoption of the proposed legislation.

This event is your unique opportunity for access to top agency officials to discuss topical issues. Now in its third year, this forum has become the “talk of the town” as the place to have a working dialog between your peers in the GP environment, including the agencies, law firms and industry. The unique venue is designed for experienced GP professionals, fostering discussion on operational issues and challenges across the programs.

The GP Town Hall forum begins with a discussion on the current status of health care legislation, including the policy and operational impacts on Government Programs. Each subsequent session throughout the day focuses on general topics across programs as well as specific programs. There are no formal slides or presentations. Each program session covers topical issues and challenges and will have various perspectives, including those from agencies, legal, industry and consultants. Attendees are invited to participate in the discussion and to ask questions to the panel members.

John Warren, Medicare Part B, Centers for Medicare and Medicaid Services

Joe Metro, Partner, Reed Smith

Katie Lapins, Director, Compliance Implementation Services

William Baxter, GP Consultant, Compliance Implementation Services

KEY TOPICS AND QUESTIONS

New Challenges in Managing the Government Business – What does healthcare reform mean to the government and commercial businesses? What is the timing of any reform and what are the key considerations for manufacturers when making projections?

Restatements and Recalculations – What are the rules and guidelines for recalculations and restatements across the programs? How do the requirements of the programs differ? What are the operational challenges associated with a recalculation and restatement?

Mergers, Acquisitions and Divestitures – How do companies manage their reporting responsibilities in the complex environment of the acquisition of companies and/or products, as well as sales and divestiture of products? What level of due diligence in GP should companies do when they are contemplating M&A activity?

Topical Policy and Operational Issues – What are the “hot topics” in policy and operational issues across Medicaid, Medicare Part B, OPA/PHS and the VA?

KEY TAKEAWAYS FOR 2010

Quantify the impact by product for your company of the new Health Care Reform

Streamline your auditing, monitoring and processing operations for compliance with government contracts

Identify the changes to government price reporting entities processes and how they interrelate

Map the impact of the chargeback process on government programs

Ensure compliance with implementation of the changes to Tricare, 340B, MDRP

Clarify Class of Trade designation and validation and lessons to clean up bad data

Avoid a false claims act violation from incorrect policies, procedures, and systems providing inaccurate information to the government

Implement effective vigilance and management of wholesaler reverse chargeback processes and criteria validation that is currently decreasing your company’s bottom line

Prevent overpayments for chargebacks from wholesalers and incentive rebates from pharmacies

Discuss how to recover lost chargeback dollars and learn new strategies to create more operational process awareness for wholesalers and manufacturers

2 comments:

Thank you for your support of the Government Programs Summit that Chris and some of the other Commercial Compliance team here at CIS are going to be leading in February. We hope that you and all the Drug Channels readers are able to join us for a great event focused on gaining insights from various Government agencies and industry experts.

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels Institute, or any of its employees.